{{Rsnum
|rsid=17647532
|Gene=GALNT1
|Chromosome=18
|position=35654108
|Orientation=plus
|GMAF=0.1038
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=GALNT1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 17.2 | 82.8
| HCB | 0.0 | 11.1 | 88.9
| JPT | 0.0 | 4.4 | 95.6
| YRI | 6.5 | 16.1 | 77.4
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 11.1 | 88.9
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}
[[rs17647532]] is a SNP in the [[GALNT1]] gene that has a variant rarely seen in [[ovarian cancer]], which may indicate it is a protective genotype. In a study of 829 patients, the [[rs17647532]](C;C) homozygous genotype was calculated to have an odds ratio for developing [[ovarian cancer]] of 0.07 (CI: 0.01-0.53, p=0.00017).{{PMID|18268124|OA=1
}}

Unfortunately, perhaps, a subsequent (larger) study by the same authors using 6,965 cases and 8,377 controls from 14 studies forming the Ovarian Cancer Association Consortium was not able to find any significant association between this SNP and risk for (or from) ovarian cancer. As the authors state, "this study underscores the need for replication of putative findings in genetic association studies".{{PMID|20142253|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}